Personalised insulin calculator enables safe and effective correction of hyperglycaemia prior to FDG PET/CT.
Diabetes mellitus
FDG PET/CT
Hyperglycaemia
Insulin
Journal
EJNMMI research
ISSN: 2191-219X
Titre abrégé: EJNMMI Res
Pays: Germany
ID NLM: 101560946
Informations de publication
Date de publication:
08 Feb 2019
08 Feb 2019
Historique:
received:
25
11
2018
accepted:
24
01
2019
entrez:
10
2
2019
pubmed:
10
2
2019
medline:
10
2
2019
Statut:
epublish
Résumé
Hyperglycaemia can influence This is a retrospective audit of all patients treated with insulin for hyperglycaemia (BGL > 10 mmol/L) prior to FDG PET/CT at the Peter MacCallum Cancer Centre over a 2-year period. Cohort 1 comprised a 12-month period (April 1, 2014-March 31, 2015) using the department's established empiric-dose insulin protocol, and Cohort 2 the 12 months (April 1, 2015-March 31, 2016) following introduction of a personalised insulin calculator protocol. Variables including body mass index, insulin-dose calculated and/or administered, BGL at baseline and nadir, and time to FDG injection were analysed. There were 115 and 136 patients treated with insulin in Cohorts 1 and 2 respectively, with similar baseline variables including mean BGL (14.5 vs 14.4 mmol/L) and range (10.5-22.7 vs 10.4-24.3 mmol/L). Use of the new personalised insulin calculator resulted in significantly fewer hypoglycaemic events (0.7% vs 5.2%; P < 0.03), shorter median time from insulin to FDG injections (108 min vs 136 min; P < 0.001) and greater individualised range in insulin prescription (3-32 IU vs 4-20 IU). The majority of patients (88.3%) receiving the personalised insulin calculator prescribed dose achieved BGL < 10.0 mmol/L. All scans obtained were of diagnostic quality. The use of our personalised insulin calculator protocol effectively lowered BGL to the target range, resulted in significantly fewer hypoglycaemic events and reduced median time between insulin and FDG injection compared to a pre-existing empiric protocol whilst achieving diagnostic scans.
Sections du résumé
BACKGROUND
BACKGROUND
Hyperglycaemia can influence
RESULTS
RESULTS
This is a retrospective audit of all patients treated with insulin for hyperglycaemia (BGL > 10 mmol/L) prior to FDG PET/CT at the Peter MacCallum Cancer Centre over a 2-year period. Cohort 1 comprised a 12-month period (April 1, 2014-March 31, 2015) using the department's established empiric-dose insulin protocol, and Cohort 2 the 12 months (April 1, 2015-March 31, 2016) following introduction of a personalised insulin calculator protocol. Variables including body mass index, insulin-dose calculated and/or administered, BGL at baseline and nadir, and time to FDG injection were analysed. There were 115 and 136 patients treated with insulin in Cohorts 1 and 2 respectively, with similar baseline variables including mean BGL (14.5 vs 14.4 mmol/L) and range (10.5-22.7 vs 10.4-24.3 mmol/L). Use of the new personalised insulin calculator resulted in significantly fewer hypoglycaemic events (0.7% vs 5.2%; P < 0.03), shorter median time from insulin to FDG injections (108 min vs 136 min; P < 0.001) and greater individualised range in insulin prescription (3-32 IU vs 4-20 IU). The majority of patients (88.3%) receiving the personalised insulin calculator prescribed dose achieved BGL < 10.0 mmol/L. All scans obtained were of diagnostic quality.
CONCLUSIONS
CONCLUSIONS
The use of our personalised insulin calculator protocol effectively lowered BGL to the target range, resulted in significantly fewer hypoglycaemic events and reduced median time between insulin and FDG injection compared to a pre-existing empiric protocol whilst achieving diagnostic scans.
Identifiants
pubmed: 30737563
doi: 10.1186/s13550-019-0480-2
pii: 10.1186/s13550-019-0480-2
pmc: PMC6368634
doi:
Types de publication
Journal Article
Langues
eng
Pagination
15Subventions
Organisme : Australian National Health and Medical Research Foundation Practitioner Fellowship
ID : NHMRC APP1108050
Références
Eur J Nucl Med Mol Imaging. 2002 Oct;29(10):1324-7
pubmed: 12271414
Clin Positron Imaging. 1998 Dec;1(1):15-30
pubmed: 14516605
Clin Positron Imaging. 1999 Oct;2(5):281-287
pubmed: 14516652
J Nucl Med. 2006 May;47(5):885-95
pubmed: 16644760
J Nucl Med. 2006 Jun;47(6):1059-66
pubmed: 16741317
PLoS Med. 2006 Nov;3(11):e442
pubmed: 17132052
J Clin Endocrinol Metab. 2009 Mar;94(3):709-28
pubmed: 19088155
J Nucl Med. 2009 Feb;50(2):178-83
pubmed: 19164226
J Nucl Med. 2010 Mar;51(3):497; author reply 498
pubmed: 20150262
J Nucl Med. 2010 Jul;51(7):1015-20
pubmed: 20554733
Nucl Med Commun. 2013 Mar;34(3):271-5
pubmed: 23250295
Nucl Med Rev Cent East Eur. 2013;16(2):57-61
pubmed: 24068633
J Nucl Med Technol. 2014 Mar;42(1):5-13
pubmed: 24503347
Nucl Med Commun. 2014 May;35(5):459-65
pubmed: 24535382
Diabetes Care. 2014 Nov;37(11):3124-31
pubmed: 25342831
Eur J Nucl Med Mol Imaging. 2015 Feb;42(2):328-54
pubmed: 25452219
Acta Oncol. 2016 Sep - Oct;55(9-10):1196-1203
pubmed: 27142123
Ann Nucl Med. 2016 Nov;30(9):629-636
pubmed: 27392947
Metabolism. 2018 Jan;78:141-154
pubmed: 28993227
J Nucl Med. 1993 Jan;34(1):1-6
pubmed: 8418248
Eur J Nucl Med. 1997 Jun;24(6):678-82
pubmed: 9169578
J Nucl Med. 1998 Jun;39(6):1030-3
pubmed: 9627339